Vjhemonc Video Journal Of Hematology Hemonc

CLL at a genomic level 2:13
CLL at a genomic level VJHemOnc – Video Journal of Hematology & HemOnc 83 3 года назад
Managing patients with multiple myeloma who have failed CAR-T therapy 1:12
Managing patients with multiple myeloma who have failed CAR-T therapy VJHemOnc – Video Journal of Hematology & HemOnc 116 4 дня назад
Developments in the treatment of FL and selecting between bispecifics and CAR-T for patients 2:07
Developments in the treatment of FL and selecting between bispecifics and CAR-T for patients VJHemOnc – Video Journal of Hematology & HemOnc 67 3 дня назад
Welcome to the Video Journal of Hematology & Hematological Oncology 🩸 3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🩸 VJHemOnc – Video Journal of Hematology & HemOnc 487 3 месяца назад
The transformation of marginal zone lymphoma to Hodgkin lymphoma 1:30
The transformation of marginal zone lymphoma to Hodgkin lymphoma VJHemOnc – Video Journal of Hematology & HemOnc 50 5 дней назад
Frontline treatment for CLL: the changing paradigm 1:31
Frontline treatment for CLL: the changing paradigm VJHemOnc – Video Journal of Hematology & HemOnc 113 12 дней назад
Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AML 2:42
Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AML VJHemOnc – Video Journal of Hematology & HemOnc 266 1 год назад
The role of bispecifics in WM 0:51
The role of bispecifics in WM VJHemOnc – Video Journal of Hematology & HemOnc 310 1 год назад
How Are ET, PV and Myelofibrosis Monitored? 9:04
How Are ET, PV and Myelofibrosis Monitored? Patient Empowerment Network 885 1 год назад
Ongoing studies in HR-MDS: VERONA and SELECT MDS-1 1:29
Ongoing studies in HR-MDS: VERONA and SELECT MDS-1 VJHemOnc – Video Journal of Hematology & HemOnc 78 2 недели назад
Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more 13:39
Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more VJHemOnc – Video Journal of Hematology & HemOnc 2,092 1 год назад
The role of covalent BTKis in the management of CLL 2:16
The role of covalent BTKis in the management of CLL VJHemOnc – Video Journal of Hematology & HemOnc 74 12 дней назад
Advice for community hematologists when prescribing bispecific antibodies for multiple myeloma 3:07
Advice for community hematologists when prescribing bispecific antibodies for multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 92 2 месяца назад
Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial? 2:56
Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial? VJHemOnc – Video Journal of Hematology & HemOnc 67 4 дня назад
The importance of nutrition in hematology and cancer care 3:10
The importance of nutrition in hematology and cancer care VJHemOnc – Video Journal of Hematology & HemOnc 225 4 месяца назад
Hematology Lecture 1:46:07
Hematology Lecture Alex Sargsyan 69,304 7 лет назад
Challenges in the treatment and management of ET and the need to improve therapeutic approaches 5:21
Challenges in the treatment and management of ET and the need to improve therapeutic approaches VJHemOnc – Video Journal of Hematology & HemOnc 4,783 2 года назад
Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL 2:49
Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL VJHemOnc – Video Journal of Hematology & HemOnc 223 1 месяц назад
Clinical features, complications, and outcomes of familial Waldenström’s macroglobulinemia 1:52
Clinical features, complications, and outcomes of familial Waldenström’s macroglobulinemia VJHemOnc – Video Journal of Hematology & HemOnc 219 5 дней назад
The prognostic value of CD34+CD38- leukemic stem cell frequency in AML 1:20
The prognostic value of CD34+CD38- leukemic stem cell frequency in AML VJHemOnc – Video Journal of Hematology & HemOnc 534 1 год назад
The mechanism of action of navtemadlin and its role in MF 1:39
The mechanism of action of navtemadlin and its role in MF VJHemOnc – Video Journal of Hematology & HemOnc 83 1 год назад
Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL 2:52
Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 519 1 год назад
Progress in the categorization and treatment of LR-MDS 3:37
Progress in the categorization and treatment of LR-MDS VJHemOnc – Video Journal of Hematology & HemOnc 54 4 дня назад
Master class in transplantation and hematology: highlights 3:40
Master class in transplantation and hematology: highlights VJHemOnc – Video Journal of Hematology & HemOnc 47 4 года назад
The value of exploring lifestyle medicine in hematology 2:43
The value of exploring lifestyle medicine in hematology VJHemOnc – Video Journal of Hematology & HemOnc 185 1 год назад
Updates on menin inhibitors for acute leukemia and the pushback of revumenib approval 2:22
Updates on menin inhibitors for acute leukemia and the pushback of revumenib approval VJHemOnc – Video Journal of Hematology & HemOnc 96 5 дней назад
An insight into the aims of the Eurasian Hematology-Oncology Group 2:26
An insight into the aims of the Eurasian Hematology-Oncology Group VJHemOnc – Video Journal of Hematology & HemOnc 34 1 год назад
An overview of the practical challenges in approaching R/R amyloidosis 1:38
An overview of the practical challenges in approaching R/R amyloidosis VJHemOnc – Video Journal of Hematology & HemOnc 28 2 месяца назад
Looking forward to ISAL 2023 1:01
Looking forward to ISAL 2023 VJHemOnc – Video Journal of Hematology & HemOnc 116 1 год назад

Сейчас ищут